Venus Remedies Share Price
1710.00+8.10 (+0.48%)
+265.27% past 1 Year
News
Venus Remedies Q1 EBITDA surges with sharp expansion in operating margins YoY
Equity
VENUSREM
Venus Remedies Q1 revenue rises sharply on higher year on year sales
Equity
VENUSREM
Venus Remedies posts strong Q1 consolidated net profit growth year on year
Equity
VENUSREM
Venus Remedies Q4 EBITDA more than doubles with sharp margin expansion
Equity
VENUSREM
Venus Remedies reports higher Q4 net profit and revenue
Equity
VENUSREM
Venus Remedies secures Saudi FDA nod for Plerixafor cancer therapy export
Equity
VENUSREM
Venus Remedies - Quaterly Results
Equity
VENUSREM
Venus Remedies Reports Strong Q3 EBITDA Growth to Rs 38 Crores, Margin Expands to 21.11%.
Equity
VENUSREM
Venus Remedies Q3 Consolidated Net Profit Rises 30.6% YoY to Rs 25.60 Crores.
Equity
VENUSREM
Venus Remedies reports Profit after tax of 24.92 Crores, in the December 2025 quarter
Equity
VENUSREM
Venus Remedies Receives Rs 2.50 Crore Under PLI Scheme, Completing Rs 10 Crore FY 2022-23 Incentive.
Equity
VENUSREM
Venus Remedies informs about board meeting
Equity
VENUSREM
Venus Remedies soars on getting marketing authorization in Indonesia for Ceftazidime + Avibactam
Equity
VENUSREM
Venus Remedies gets marketing authorization in Indonesia for Ceftazidime + Avibactam
Equity
VENUSREM
Venus Remedies secures Indonesia approval for key antibiotic combination
Equity
VENUSREM
Venus Remedies informs about press release
Equity
VENUSREM
Venus Remedies Q2 FY26: Net Profit Soars, EBITDA Margin Expands Sharply Year-On-Year
Equity
VENUSREM
Venus Remedies: Q1 Ebitda 10.10 Crores Rupees Vs 11.30 Crores (Yoy) || Q1 Ebitda Margin 7.66% Vs 10.37% (Yoy)
Equity
VENUSREM
Venus Remedies: Q1 Cons Net Profit 9.60 Crores Rupees Vs 1.20 Crores (Yoy) || Q1 Revenue 132.00 Crores Rupees Vs 109.00 Crores (Yoy)
Equity
VENUSREM
Venus Remedies - Quaterly Results
Equity
VENUSREM